<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01883167</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-105</org_study_id>
    <nct_id>NCT01883167</nct_id>
  </id_info>
  <brief_title>RDEA3170 and Febuxostat Drug Interaction Study</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Febuxostat in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD)
      interaction between the XO inhibitor febuxostat and the investigational URAT1 inhibitor
      RDEA3170 and provide information for potential future clinical studies using this
      combination. Combination treatment using 2 drugs with different mechanisms of action may
      achieve improved response and may allow the use of lower doses, resulting in fewer side
      effects than the use of either drug alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of RDEA3170 from plasma and urine and febuxostat from plasma</measure>
    <time_frame>Days -1 (urine only), 7, 14, 21 and Days 8, 15, 22 (plasma only)</time_frame>
    <description>Profile from plasma and urine in terms of AUC, Tmax, Cmax, t1/2, Ae, and CLr
AUC: area under the concentration-time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life; Ae: amount excreted of unchanged drug into urine; CLr: renal clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD profile of RDEA3170 and febuxostat alone and in combination</measure>
    <time_frame>Days -1, 7, 14, 21 and Days 8, 15, 22 (serum only)</time_frame>
    <description>Profile from serum and urine in terms of sUA concentration, renal clearance of uric acid, urine uric acid excretion amounts, and fractional excretion of uric acid.
sUA: serum urate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.
Days 15-21: RDEA3170 10 mg or placebo qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA3170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.
Days 15-21: febuxostat 40 mg qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 10 mg</intervention_name>
    <description>RDEA3170 10 mg once daily (qd)</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>RDEA3170</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat 40 mg</intervention_name>
    <description>Febuxostat 40 mg qd</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>RDEA3170</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo qd</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>RDEA3170</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.

          -  no clinically relevant abnormalities in vital signs, ECG, physical examination or
             safety laboratory values, per the Investigator's judgment.

          -  a screening serum urate level ≥ 4.5 mg/dL.

        Exclusion Criteria:

          -  history or suspicion of kidney stones.

          -  history of cardiac abnormalities as assessed during screening, including abnormal and
             clinically relevant electrocardiogram changes and/or family history of sudden death in
             otherwise healthy individual between the ages of 1 and 30 years.

          -  undergone major surgery within 3 months prior to Day 1.

          -  donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior
             to Day 1 or gave a plasma donation within 4 weeks prior to the Screening Period.

          -  inadequate venous access or unsuitable veins for repeated venipuncture.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Baumgartner</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

